Skip to content
Poster

Hepatoprotective effects of a HSD17b13 inhibitor in the CDAA-HFD mouse model of advanced MASH with progressive fibrosis

Background & Aim:
HSD17B13, a newly identified hepatocyte-specific, lipid droplet-associated protein, has recently been reported to be closely associated with the development and progression of MASLD/MASH. Additionally, inhibition of HSD17B13 has demonstrated protective effects against liver fibrosis in preclinical models of MASH.

The present study aimed to evaluate the effects of an HSD17B13 inhibitor following interventional therapy in the non-obese choline-deficient L-amino acid-defined high-fat diet (CDAA-HFD) mouse model of advanced MASH with progressive fibrosis.

Subjects
MouseCDAA-HFD mouseBody weightBlood biochemistryBioinformaticsMetabolic dysfunction-associated steatohepatitisHistopathology scoreHSD17b13Image analysisImmunohistochemistry (IHC)Liver morphometryNext-generation sequencingHSD17b13 inhibitorRNA sequencing

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top